The UK and US have established a important trade agreement that will preserve no tariffs on UK medicine exports entering the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to increase funding on drugs through the NHS. This move secures that tariffs on these vital goods will be held at nothing for a timeframe of the next three years.
This deal comes after previous warnings to hike import taxes on patented drug products, with potential rates discussed reaching 100%.
"This deal between the United Kingdom strengthens the international landscape for innovative medicines and introduces much-needed balance to U.S.–U.K. medicine commerce," a release declared.
Commercial Impact
Pharmaceuticals represent one of the Britain's most significant export categories to the America, which is by far the primary buyer for leading companies like GSK and AstraZeneca.
Trade data show that in the 12 months prior to last September, the UK exported pharmaceutical products totaling over eleven billion pounds to the US. This value accounted for 17.4% of total UK exports in that timeframe.
"This agreement safeguards work, boosts capital expenditure and sets the stage for the UK to emerge as a worldwide center for medical research," a minister commented.
Specific UK Commitments
The pact involves several specific commitments from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it deems new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to double overall health service expenditure on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to control costs will be restricted at fifteen percent. Previously, rebates exceeded 20%.
Industry Background
The pact takes place against a ongoing row between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
The disagreement were heightened by assertions that US patients were paying several times more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while substantial investments have been pledged toward US facilities.
One official publicly accepted that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had declined as a percentage of its overall budget over the previous ten-year period.
